Drugs / FB2001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05583812 | Oct → Dec 2022 | COVID-19 | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05197179 | Dec 2021 → Apr 2022 | COVID-19 | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04766931 | Mar 2021 → Aug 2022 | COVID-19 | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05415241 | Jun → Aug 2022 | — | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05675072 | Jan → Sep 2023 | — | Frontier Biotechnologies Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05445934 | Sep 2022 → Nov 2023 | COVID-19 | Frontier Biotechnologies Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04766931 ↗ |
| Action | Inhibit | “FB2001 is a small-molecule inhibitor of coronavirus 3CL protease (3CLpro).” NCT05445934 ↗ |
| Modality | Small molecule | “FB2001 is a small-molecule inhibitor” NCT05445934 ↗ |
| Route | Intravenous | “administered with FB2001 by intravenous (IV) infusion” NCT04766931 ↗ |